PD-L1 antibody + bevacizumab + liver chemo for advanced liver cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether combining a PD-L1 antibody (an immunotherapy) with bevacizumab (a drug that slows blood vessel growth to tumors) and a liver-directed chemotherapy infusion can help people with advanced liver cancer that has spread outside the liver. It is designed for patients who have not previously received these specific treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of liver cancer (hepatocellular carcinoma) that has spread beyond the liver and cannot be removed with surgery.
- You must not have had prior treatment with PD-L1 inhibitors or bevacizumab (Avastin).
- You must be between 18 and 75 years old and be in fairly good health (ECOG score 0 or 1, meaning you can do daily activities).
- Your liver function must be at least moderately preserved (Child-Pugh class A or B7).
- You must not have serious liver complications, active infections, or other uncontrolled medical conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
This trial tests a new combination treatment for liver cancer that cannot be removed with surgery. It combines targeted therapy and immunotherapy with a procedure that delivers chemotherapy directly to the liver, aiming to shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy drug (adebrelimab) and a targeted therapy (bevacizumab) given through a vein or directly into the liver artery, along with standard chemotherapy directly into the liver artery, for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this approach can shrink or control the cancer.
This trial is for people with liver cancer that cannot be removed by surgery. It tests whether adding a targeted therapy (lenvatinib) to the current combination of bevacizumab and an immunotherapy (PD-1 inhibitor) works better than continuing without lenvatinib, for those whose disease progressed after initial treatment.
This trial tests a combination of immunotherapy (checkpoint inhibitors) and anti-VEGF therapy (which blocks blood vessel growth to tumors) with or without local treatments (like chemoembolization) for advanced liver cancer. It aims to see if the combination works better than current treatments.
This study combines a liver-directed procedure called TACE (which blocks blood flow to the tumor and delivers chemotherapy directly to it) with two immunotherapy drugs and a targeted therapy (bevacizumab). The goal is to see if this combination can shrink liver cancer that cannot be surgically removed, without the cancer having spread elsewhere.
Hear when a new Hepato Cellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.